Back to News
Market Impact: 0.15
Abbott Laboratories Amulet 360 Achieves 98% Stroke-Free Rate In VERITAS Study
Source: Nasdaq
Healthcare & Biotech
Abbott Laboratories announced one-year results from the VERITAS study evaluating the safety and effectiveness of its investigational Amulet 360 Left Atrial Appendage Occluder; the article provides no specific results or outcome figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ABT0.20
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Bright Minds shares fall as BTIG cuts price target on clinical hold
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Vertex Pharma meets Q3 estimates, raises revenue guidance